Developer docs
API playgroundTry for free, no card

Search company profiles

BlueWind Medical

Full company profile

uuid0000oe6

Namestring
BlueWind Medical
Legal namestring
BlueWind Medical, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

BlueWind Medical is a privately held medical device company founded in 2010 by the Rainbow Medical Group and headquartered in Salt Lake City, Utah, with additional operations in Herzliya, Israel (R&D and engineering) and Galway, Ireland (EMEA). The company develops and commercializes the Revi System, an implantable tibial neuromodulation platform for the treatment of urge urinary incontinence (UUI) in adults. The system consists of a 3 cm × 3 mm leadless, battery-less implant placed near the tibial nerve in the ankle during a single outpatient procedure under local anesthesia, wirelessly powered by an external battery-operated Revi Wearable (~30 min/day of therapy). The platform is completed by an iPad-based Clinician Programmer for parameter customization and a Revi Hub that wirelessly transmits therapy data back to the clinician. The 10-year implant lifetime and MR Conditional (1.5T/3T) status are core design differentiators relative to traditional sacral neuromodulation.

The Revi System received FDA De Novo classification in August 2023 — making it the first FDA-cleared implantable neuromodulation device usable without prior failure on more conservative treatments — followed by FDA 510(k) clearance for an enhanced Revi Wearable in December 2025. Three-year OASIS pivotal data (N=151 enrolled, 23 centers across U.S./U.K./Europe; N=90 completers) showed 95% patient satisfaction, 79% with ≥50% UUI reduction, 63% with ≥75% reduction, and 28% dry on a 3-day diary at 36 months, with no device- or procedure-related serious adverse events. The OASIS data and 2024 AUA/SUFU idiopathic OAB guideline inclusion allow Revi to be considered earlier in the treatment journey.

BlueWind generates revenue primarily through hardware sales of the Revi System (Implant + Wearable + Clinician Programmer + Hub) to healthcare providers and outpatient facilities, with a recurring replacement stream from the 1-year service-life Wearable. CMS proposed a 2025 reimbursement rate of ~$19,464 per subfascial implantable tibial neuromodulation procedure — a ~38% YoY increase. The company goes to market via direct field sales to urologists and urogynecologists, a state-by-state U.S. rollout (Louisiana, Ohio, Texas, Utah, Florida), a provider self-service digital portal, and a patient-facing awareness motion; patient access is supported by the Revi Access program (powered by JDL Access) for prior authorization and appeals. Disclosed funding totals at least $111.8M ($64M in May 2022 and $47.8M in May 2026), and the company won the 2025 MedTech Breakthrough "Best New Technology Solution – Therapeutics" award.

Short descriptiontext

BlueWind Medical commercializes the Revi System, a leadless, battery-less implantable tibial neuromodulation platform for treating urge urinary incontinence in adults. Founded in 2010 by the Rainbow Medical Group, the Salt Lake City-based company received FDA De Novo in August 2023 and raised $47.8M in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tibial neuromodulation systems, implantable neurostimulation devices, urinary incontinence treatment, wireless peripheral nerve stimulation, overactive bladder therapy
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Neuromodulation Devices
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Revi System hardware sales (implant + wearable + clinician programmer + hub)
TypeHardware Sales
Description

Revenue from sale of the Revi neuromodulation system to healthcare providers/hospitals that perform the outpatient implantation procedure; aligned with expanding the commercial sales organization and broader market access.

femtechinsider.com
2Revi Wearable device replacement (1-year service life)
TypeHardware Sales
Description

Revi Wearable Device has a stated service life of 1 year, implying recurring replacement revenue from the external wearable component, separate from the 10-year implant lifespan.

bluewindmedical.com
3Patient access / reimbursement support services via Revi Access
TypeManaged Services
Description

Revi Access (powered by partner JDL Access) supports providers and patients through prior authorizations, pre-service appeals, post-service appeals and external review (IRO) submissions, supporting realized reimbursement and procedure volume.

bluewindmedical.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations, Infrastructure
Pricing details1 tier
1CMS-reimbursed procedure (proposed 2025 rate ~$19,464, ~38% YoY increase)
ModelOtherBilling cadenceOther
Notes

2025 CMS proposed reimbursement rate of $19,464 for the subfascial implantable tibial neuromodulation procedure, representing a 38% increase over the prior year. Prior reimbursement (per MassDevice coverage) was reported at $21,444 in one year, illustrating rate evolution. Coverage and patient cost depend on individual insurance; Traditional Medicare has no prior authorization, Commercial/Medicare Advantage may.

openpr.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BlueWind Medical develops and sells the Revi System, an implantable tibial neuromodulation platform for treating urge urinary incontinence (UUI) in adults. The system comprises a miniature leadless, battery-less implant (3 cm long, 3 mm diameter) placed near the tibial nerve in a single outpatient procedure, wirelessly powered by an external battery-operated Wearable, plus a clinician programmer (iPad-based) and a Hub that transmits therapy data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 95% patient satisfaction with Revi therapy at 36 months (OASIS completers, N=87)
+6 more records
Product overview1 text field

BlueWind Medical's offering is a single unified neuromodulation platform, the Revi® System, for treating urgency urinary incontinence (UUI) in adults. The platform is composed of four integrated hardware components that work together: the Revi Implant (a 3 cm leadless tibial implant), the Revi Wearable (an external battery-powered activator worn on the ankle), the Revi Clinician Programmer (an iPad-based clinician tool for parameter customization), and the Revi Hub (a wireless communicator that relays therapy data to clinicians). Together these deliver a single-procedure, externally-powered, MR-conditional therapy with no implanted battery and no leads. Surrounding the device, BlueWind also operates Revi Access (powered by JDL Access), a non-device patient access service that supports prior authorization and insurance appeals for the therapy.

Product and service6 records
1Revi System
CategoryImplantable neuromodulation platform
Description

Integrated implantable tibial neuromodulation therapy for urgency urinary incontinence (UUI) in adults, consisting of a miniature leadless tibial implant activated wirelessly by an external battery-powered Wearable, plus a Clinician Programmer and Hub; delivered via a single outpatient procedure under local anesthesia. Designed for adult patients with UUI and the urologists/urogynecologists who implant it.

2Revi Implant
CategoryImplanted leadless stimulator
Description

Miniature battery-less implant (3 cm long, 3 mm in diameter) placed in the ankle region near the tibial nerve during a single outpatient procedure under local anesthesia. Delivers tibial neuromodulation via subfascial placement with direct visualization of the tibial nerve, intraoperative testing, and suture fixation. MR Conditional for 1.5T and 3T full body MR scans; 10-year implant lifetime. A component of the Revi System, sold to healthcare providers implanting it in UUI patients.

3Revi Wearable (Enhanced)
CategoryExternal activator/controller
Description

Battery-operated external wearable worn around the ankle that wirelessly powers the Revi Implant and delivers therapy on the patient's schedule. Supports multiple pre-set treatment programs patients can adjust; water-resistant with a 1-year service life. A component of the Revi System, sold to healthcare providers for patient use.

4Revi Clinician Programmer
CategoryClinician configuration tool
Description

iPad-based clinician programmer that customizes Revi therapy for each patient by adjusting frequency, pulse width, polarity, and amplitude, and supports intra-operative testing and post-implant reprogramming. Functions as a monitor during the surgical procedure outside the sterile field. A component of the Revi System, sold to healthcare providers.

5Revi Hub
CategoryTherapy data communicator
Description

Wireless home communicator that automatically receives therapy data from the Revi Wearable when placed nearby, giving clinicians visibility into device usage and status to support and optimize patient therapy. A component of the Revi System, sold to healthcare providers.

6Revi Access (powered by JDL Access)
CategoryPatient access service program
Description

Patient access support program powered by third-party partner JDL Access that helps providers and patients obtain insurance coverage for the Revi System via prior authorization submissions, pre-service and post-service claims appeals, eligibility/benefit verification, and external independent review organization (IRO) submissions.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCore Operational PartnerTypeImplementation/ SI/ Consulting Partner
Description

Powers the 'Revi Access' patient access program for BlueWind. JDL Access works directly with healthcare providers and patients' insurance companies to submit prior authorizations, pre-service and post-service appeals, and external (IRO) reviews until a final coverage decision is reached. Integrated into the provider enrollment workflow and offered to enrolled physician offices.

2MDMA (Medical Device Manufacturers Association)
Strategic tierMinor / CommunityTypeOthers
Description

BlueWind Medical is a proud member of MDMA, displayed on the Compliance page with a logo linking to the MDMA membership site — a trade association for the medical device industry.

bluewindmedical.com
3AUA / SUFU (American Urological Association / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction)
TypeOthers
bluewindmedical.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets onabotulinumtoxinA (Botox) for idiopathic OAB. Established third-line procedural therapy for UUI and a direct competitor for the refractory patient segment BlueWind is targeting with Revi.

TypeEmerging player
Description

Develops the eCoin leadless, coin-sized implantable tibial neuromodulation device for urge urinary incontinence. Closest direct implant-form-factor competitor to Revi, with overlapping regulatory and clinical positioning.

3Axonics (Boston Scientific)
TypeDirect peer
Description

Sacral neuromodulation competitor to Revi in OAB/urinary incontinence, now owned by Boston Scientific. Offers miniaturized, MRI-conditional SNM systems targeting the same urology provider base that BlueWind is building out.

TypeOthers
Description

Wound, ostomy, continence and infusion care company that participated in BlueWind's 2022 $64M financing round and whose executive Evy Douglas sits on BlueWind's board. Ecosystem/investor peer with adjacent continence-care commercial overlap.

TypeBroad incumbent
Description

Large urology-focused medical device company offering a broad portfolio of diagnostic and therapeutic urology products. Acquired Cogentix/Urgent PC and competes with BlueWind through both tibial neuromodulation and adjacent urology categories.

TypeBroad incumbent
Description

Public neuromodulation company with an FDA-approved, implanted hypoglossal nerve stimulator for obstructive sleep apnea. Comparable specialty-neuromodulation commercial model and reimbursement-build playbook, though in a different therapeutic indication.

TypeDirect peer
Description

Markets the InterStim sacral neuromodulation system for OAB and UUI. Directly competes with BlueWind's Revi in the same urology call point, though Medtronic's technology is sacral (not tibial) and uses a traditional implanted battery and lead.

TypeBroad incumbent
Description

Urology-focused company commercializing vibegron (GEMTESA) for OAB, the leading oral pharmacotherapy competitor. Indirectly competes with Revi for the same UUI patient pool, particularly relevant given high medication discontinuation rates.

TypeEmerging player
Description

Miniaturized, wirelessly powered neuromodulation platform pursuing urology and other indications. Adjacent technology peer with overlapping miniaturized, battery-less implant architecture relevant to BlueWind's IP approach.

10Cogentix Medical (now part of Laborie)
TypeDirect peer
Description

Markets the Urgent PC percutaneous tibial neuromodulation system for OAB. The most direct non-implantable competitor to Revi in tibial neuromodulation, addressing the same patient population with a non-implant approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BlueWind Medical

Implantable Neuromodulation Devicesbluewindmedical.com

BlueWind Medical commercializes the Revi System, a leadless, battery-less implantable tibial neuromodulation platform for treating urge urinary incontinence in adults. Founded in 2010 by the Rainbow Medical Group, the Salt Lake City-based company received FDA De Novo in August 2023 and raised $47.8M in 2026.

What BlueWind Medical does

BlueWind Medical is a privately held medical device company founded in 2010 by the Rainbow Medical Group and headquartered in Salt Lake City, Utah, with additional operations in Herzliya, Israel (R&D and engineering) and Galway, Ireland (EMEA). The company develops and commercializes the Revi System, an implantable tibial neuromodulation platform for the treatment of urge urinary incontinence (UUI) in adults. The system consists of a 3 cm × 3 mm leadless, battery-less implant placed near the tibial nerve in the ankle during a single outpatient procedure under local anesthesia, wirelessly powered by an external battery-operated Revi Wearable (~30 min/day of therapy). The platform is completed by an iPad-based Clinician Programmer for parameter customization and a Revi Hub that wirelessly transmits therapy data back to the clinician. The 10-year implant lifetime and MR Conditional (1.5T/3T) status are core design differentiators relative to traditional sacral neuromodulation.

The Revi System received FDA De Novo classification in August 2023 — making it the first FDA-cleared implantable neuromodulation device usable without prior failure on more conservative treatments — followed by FDA 510(k) clearance for an enhanced Revi Wearable in December 2025. Three-year OASIS pivotal data (N=151 enrolled, 23 centers across U.S./U.K./Europe; N=90 completers) showed 95% patient satisfaction, 79% with ≥50% UUI reduction, 63% with ≥75% reduction, and 28% dry on a 3-day diary at 36 months, with no device- or procedure-related serious adverse events. The OASIS data and 2024 AUA/SUFU idiopathic OAB guideline inclusion allow Revi to be considered earlier in the treatment journey.

BlueWind generates revenue primarily through hardware sales of the Revi System (Implant + Wearable + Clinician Programmer + Hub) to healthcare providers and outpatient facilities, with a recurring replacement stream from the 1-year service-life Wearable. CMS proposed a 2025 reimbursement rate of ~$19,464 per subfascial implantable tibial neuromodulation procedure — a ~38% YoY increase. The company goes to market via direct field sales to urologists and urogynecologists, a state-by-state U.S. rollout (Louisiana, Ohio, Texas, Utah, Florida), a provider self-service digital portal, and a patient-facing awareness motion; patient access is supported by the Revi Access program (powered by JDL Access) for prior authorization and appeals. Disclosed funding totals at least $111.8M ($64M in May 2022 and $47.8M in May 2026), and the company won the 2025 MedTech Breakthrough "Best New Technology Solution – Therapeutics" award.

BlueWind Medical firmographics

Firmographics
Name
BlueWind Medical
Legal name
BlueWind Medical, Inc.
Website
https://bluewindmedical.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
BlueWind Medical commercializes the Revi System, a leadless, battery-less implantable tibial neuromodulation platform for treating urge urinary incontinence in adults. Founded in 2010 by the Rainbow Medical Group, the Salt Lake City-based company received FDA De Novo in August 2023 and raised $47.8M in 2026.
Ownership category
akta.pro rank

BlueWind Medical industry classification

Industry
Product category
Implantable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Tibial neuromodulation systems
  • Implantable neurostimulation devices
  • Urinary incontinence treatment
  • Wireless peripheral nerve stimulation
  • Overactive bladder therapy

Where BlueWind Medical is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

BlueWind Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations, Infrastructure

Revenue model

  1. Revi System hardware sales (implant + wearable + clinician programmer + hub): Revenue from sale of the Revi neuromodulation system to healthcare providers/hospitals that perform the outpatient implantation procedure; aligned with expanding the commercial sales organization and broader market access.
  2. Revi Wearable device replacement (1-year service life): Revi Wearable Device has a stated service life of 1 year, implying recurring replacement revenue from the external wearable component, separate from the 10-year implant lifespan.
  3. Patient access / reimbursement support services via Revi Access: Revi Access (powered by partner JDL Access) supports providers and patients through prior authorizations, pre-service appeals, post-service appeals and external review (IRO) submissions, supporting realized reimbursement and procedure volume.

Pricing tiers

ModelBillingPrice
OtherOtherCMS-reimbursed procedure (proposed 2025 rate ~$19,464, ~38% YoY increase)

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

BlueWind Medical product offering

Product offering

Core offering

BlueWind Medical develops and sells the Revi System, an implantable tibial neuromodulation platform for treating urge urinary incontinence (UUI) in adults. The system comprises a miniature leadless, battery-less implant (3 cm long, 3 mm diameter) placed near the tibial nerve in a single outpatient procedure, wirelessly powered by an external battery-operated Wearable, plus a clinician programmer (iPad-based) and a Hub that transmits therapy data.

Product overview

BlueWind Medical's offering is a single unified neuromodulation platform, the Revi® System, for treating urgency urinary incontinence (UUI) in adults. The platform is composed of four integrated hardware components that work together: the Revi Implant (a 3 cm leadless tibial implant), the Revi Wearable (an external battery-powered activator worn on the ankle), the Revi Clinician Programmer (an iPad-based clinician tool for parameter customization), and the Revi Hub (a wireless communicator that relays therapy data to clinicians). Together these deliver a single-procedure, externally-powered, MR-conditional therapy with no implanted battery and no leads. Surrounding the device, BlueWind also operates Revi Access (powered by JDL Access), a non-device patient access service that supports prior authorization and insurance appeals for the therapy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Revi System Integrated implantable tibial neuromodulation therapy for urgency urinary incontinence (UUI) in adults, consisting of a miniature leadless tibial implant activated wirelessly by an external battery-powered Wearable, plus a Clinician Programmer and Hub; delivered via a single outpatient procedure under local anesthesia. Designed for adult patients with UUI and the urologists/urogynecologists who implant it.
  • Revi Implant Miniature battery-less implant (3 cm long, 3 mm in diameter) placed in the ankle region near the tibial nerve during a single outpatient procedure under local anesthesia. Delivers tibial neuromodulation via subfascial placement with direct visualization of the tibial nerve, intraoperative testing, and suture fixation. MR Conditional for 1.5T and 3T full body MR scans; 10-year implant lifetime. A component of the Revi System, sold to healthcare providers implanting it in UUI patients.
  • Revi Wearable (Enhanced) Battery-operated external wearable worn around the ankle that wirelessly powers the Revi Implant and delivers therapy on the patient's schedule. Supports multiple pre-set treatment programs patients can adjust; water-resistant with a 1-year service life. A component of the Revi System, sold to healthcare providers for patient use.
  • Revi Clinician Programmer iPad-based clinician programmer that customizes Revi therapy for each patient by adjusting frequency, pulse width, polarity, and amplitude, and supports intra-operative testing and post-implant reprogramming. Functions as a monitor during the surgical procedure outside the sterile field. A component of the Revi System, sold to healthcare providers.
  • Revi Hub Wireless home communicator that automatically receives therapy data from the Revi Wearable when placed nearby, giving clinicians visibility into device usage and status to support and optimize patient therapy. A component of the Revi System, sold to healthcare providers.
  • Revi Access (powered by JDL Access) Patient access support program powered by third-party partner JDL Access that helps providers and patients obtain insurance coverage for the Revi System via prior authorization submissions, pre-service and post-service claims appeals, eligibility/benefit verification, and external independent review organization (IRO) submissions.

Quantifiable outcome

  • 95% patient satisfaction with Revi therapy at 36 months (OASIS completers, N=87)
  • +6 more outcomes

Companies that use BlueWind Medical

Customer profile

Named customers1 record

Ideal customer profiles1 record

BlueWind Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BlueWind Medical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core operational partner and minor / community.

  • JDL Access (Revi Access program)core operational partnerImplementation/ SI/ Consulting PartnerPowers the 'Revi Access' patient access program for BlueWind. JDL Access works directly with healthcare providers and patients' insurance companies to submit prior authorizations, pre-service and post-service appeals, and external (IRO) reviews until a final coverage decision is reached. Integrated into the provider enrollment workflow and offered to enrolled physician offices.
  • MDMA (Medical Device Manufacturers Association)minor / communityOthersBlueWind Medical is a proud member of MDMA, displayed on the Compliance page with a logo linking to the MDMA membership site — a trade association for the medical device industry.
  • AUA / SUFU (American Urological Association / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction)Others

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

BlueWind Medical competitors and assessment

Company assessment

Broad incumbents

  • Allergan / AbbVie (Botox): Markets onabotulinumtoxinA (Botox) for idiopathic OAB. Established third-line procedural therapy for UUI and a direct competitor for the refractory patient segment BlueWind is targeting with Revi.
  • Laborie Medical Technologies: Large urology-focused medical device company offering a broad portfolio of diagnostic and therapeutic urology products. Acquired Cogentix/Urgent PC and competes with BlueWind through both tibial neuromodulation and adjacent urology categories.
  • Inspire Medical Systems: Public neuromodulation company with an FDA-approved, implanted hypoglossal nerve stimulator for obstructive sleep apnea. Comparable specialty-neuromodulation commercial model and reimbursement-build playbook, though in a different therapeutic indication.
  • Urovant Sciences (Sumitovant/Sumitomo): Urology-focused company commercializing vibegron (GEMTESA) for OAB, the leading oral pharmacotherapy competitor. Indirectly competes with Revi for the same UUI patient pool, particularly relevant given high medication discontinuation rates.

Emerging players

  • Valencia Technologies (eCoin): Develops the eCoin leadless, coin-sized implantable tibial neuromodulation device for urge urinary incontinence. Closest direct implant-form-factor competitor to Revi, with overlapping regulatory and clinical positioning.
  • Neuspera Medical: Miniaturized, wirelessly powered neuromodulation platform pursuing urology and other indications. Adjacent technology peer with overlapping miniaturized, battery-less implant architecture relevant to BlueWind's IP approach.

Direct peers

  • Axonics (Boston Scientific): Sacral neuromodulation competitor to Revi in OAB/urinary incontinence, now owned by Boston Scientific. Offers miniaturized, MRI-conditional SNM systems targeting the same urology provider base that BlueWind is building out.
  • Medtronic: Markets the InterStim sacral neuromodulation system for OAB and UUI. Directly competes with BlueWind's Revi in the same urology call point, though Medtronic's technology is sacral (not tibial) and uses a traditional implanted battery and lead.
  • Cogentix Medical (now part of Laborie): Markets the Urgent PC percutaneous tibial neuromodulation system for OAB. The most direct non-implantable competitor to Revi in tibial neuromodulation, addressing the same patient population with a non-implant approach.

Others

  • Convatec: Wound, ostomy, continence and infusion care company that participated in BlueWind's 2022 $64M financing round and whose executive Evy Douglas sits on BlueWind's board. Ecosystem/investor peer with adjacent continence-care commercial overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BlueWind Medical social profiles

Digital presence

BlueWind Medical compliance and trust

Trust signal

Compliance4 records

BlueWind Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BlueWind Medical leadership team

Management profile

Number of profiles

Profiles12 records

BlueWind Medical subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BlueWind Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BlueWind Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueWind Medical

What does BlueWind Medical do?

BlueWind Medical develops and sells the Revi System, an implantable tibial neuromodulation platform for treating urge urinary incontinence (UUI) in adults. The system comprises a miniature leadless, battery-less implant (3 cm long, 3 mm diameter) placed near the tibial nerve in a single outpatient procedure, wirelessly powered by an external battery-operated Wearable, plus a clinician programmer (iPad-based) and a Hub that transmits therapy data.

Is BlueWind Medical a public or private company?

BlueWind Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was BlueWind Medical founded?

BlueWind Medical was founded in 2010. It employs 51 to 100 people.

Where is BlueWind Medical based?

BlueWind Medical is headquartered in Salt Lake City, United States, in the North America region.

How does BlueWind Medical make money?

Three revenue lines are on record. Revi System hardware sales (implant + wearable + clinician programmer + hub) is the primary driver. The others are revi Wearable device replacement (1-year service life) and patient access / reimbursement support services via Revi Access.

Who are BlueWind Medical's main competitors?

Broad incumbents on record are Allergan / AbbVie (Botox), Laborie Medical Technologies, Inspire Medical Systems and Urovant Sciences (Sumitovant/Sumitomo). Emerging players are Valencia Technologies (eCoin) and Neuspera Medical. Direct peers are Axonics (Boston Scientific), Medtronic and Cogentix Medical (now part of Laborie). Convatec is listed as an others.

Does BlueWind Medical have an API?

No public API is recorded for BlueWind Medical.

What industry is BlueWind Medical in?

BlueWind Medical's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLALABAK, Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogBlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of PatientsHumana will cover implantable tibial neuromodulation for urgency urinary incontinence, including the Revi System, effective October 1, 2026. The decision cites BlueWind's OASIS study showing 79% of participants achieved at least 50% symptom improvement. Humana is the second-largest Medicare Advantage organization with about 11 million enrollees.Business Wire BlogBlueWind Medical Announces Category I CPT Code for Subfascial Tibial NeuromodulationBlueWind Medical announced the AMA CPT Editorial Panel approved a Category I code for subfascial tibial neuromodulation implantation, effective January 1, 2028. The Revi system shows 79% efficacy at three years and 95% patient satisfaction, with a 15-year implant life. A physician survey will inform payment valuation.FinancialContent Business PageBlueWind Medical Announces Category I CPT Code for Subfascial Tibial NeuromodulationThe AMA CPT Editorial Panel approved a new Category I code for subfascial tibial neuromodulation implantation, effective January 1, 2028. The code recognizes distinct physician work for Revi's subfascial placement, which shows 79% efficacy at three years and 95% patient satisfaction. A physician survey will inform future payment valuation.Urology TimesDr. Dmochowski on tibial nerve stimulation as an earlier line of therapy for OABRoger R. Dmochowski, MD, highlighted the FDA approval of the BlueWind Revi System, noting its potential as an earlier line of therapy for overactive bladder (OAB) patients. He is chief medical officer at BlueWind Medical and a professor at Vanderbilt University Medical Center.Contemporary OB/GYNRevi System demonstrates positive two-year results for treating urgency urinary incontinenceBlueWind Medical published 2-year results from its OASIS study on the Revi System for urgency urinary incontinence. Of 151 women, 97 completed the study, with 79% experiencing at least a 50% symptom reduction and 28% completely dry. No serious adverse events occurred, and the device requires no permanent power source.Medical Device and Diagnostic industryTibial Neuromodulation Could Disrupt the Overactive Bladder MarketBlueWind Medical launched a pivotal trial of its Renova iStim tibial neuromodulation system for overactive bladder, aiming to offer a less invasive alternative to sacral nerve stimulation. The global market is projected to reach $4.19 billion by 2022, and the company expects FDA clearance by the first half of 2023.IndianpharmapostBlueWind Medical wins FDA nod for Revi Extend expanding implant life to 15 yearsBlueWind Medical received FDA clearance for Revi Extend, an implant extending device durability from 10 to 15 years for urgency urinary incontinence. The company plans a limited US launch in Q4 2026. The implant builds on clinical results showing 79% of patients achieved at least a 50% reduction in episodes at three years.YahooBlueWind Medical lands FDA clearance for UUI implant with 15-year lifespanBlueWind Medical, a Utah-based medtech company, has received FDA clearance for its Revi Extend implantable tibial neuromodulation (ITNM) system, a next-generation urge urinary incontinence (UUI) treatment with an extended 15-year lifespan. The device, implanted near the ankle during an outpatient procedure, includes a wearable control for personalized therapy and follows the company's $47.8 million fundraising in May 2026. BlueWind plans a limited US market launch of Revi Extend in Q4 2026, entering a competitive urology space where Boston Scientific and Neuspera are also advancing neuromodulation treatments for bladder dysfunction.Medical Device NetworkBlueWind Medical lands FDA clearance for UUI implant with 15-year lifespanBlueWind Medical has received FDA clearance for Revi Extend, its next-generation implantable tibial neuromodulation system for treating urge urinary incontinence, extending the device lifespan from 10 to 15 years. The Utah-based company plans a limited US market launch in Q4 2026, following a $47.8m fundraise in May 2026 that will support commercialization efforts. The system is implanted near the ankle during an outpatient procedure and includes a wearable control allowing patients to personalize therapy.Mpo-magBlueWind Medical Wins FDA Nod for Next-Gen Tibial NeuromodBlueWind Medical received FDA 510(k) clearance for Revi Extend, its next-generation implantable tibial neuromodulation system for urinary urge incontinence, with a 15-year implant life. The company expects a limited U.S. launch in Q4 this year, following $47.8 million in financing.